Digital A look back at 2023: A Benchling biotech breakfast As we enter the New Year, and set forth into the myriad possibilities and plans of 2024, it pays to pause and reflect.
News MSD adds new indication for Welireg in rare tumours MSD's oral HIF-2 alpha inhibitor Welireg has a third FDA approval, becoming the first oral treatment for a rare solid tumour PPGL or 'pheo para'.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.
